pain drug

success failure signposts
Biotech

Vertex's pain prospect underwhelms versus placebo, sinking stock

The trial linked the molecule to a significant improvement from baseline, but placebo performed similarly, triggering a 12% drop in Vertex’s share.
Nick Paul Taylor Dec 19, 2024 7:41am
power lines at dusk

Novo Holdings-backed SiteOne charges up with $100M financing

Dec 18, 2024 7:00am
positive negative up down good bad mixed

Vertex's phase 3 pain trials hit goals but fail to beat Vicodin

Jan 30, 2024 8:00am
An artists concept of spinal pain A silhouette of a person stands holding their back The spinal cord is highlighted on the

Drug more effective on pain than gabapentin, minus side effects

Nov 14, 2023 10:00am
Graphic of arrows missing the target

Strike 3: Aptinyx's pain prospect flunks 3rd midphase trial

Aug 12, 2022 8:23am
stop light green

No pain, only gain for Vertex as FDA greenlights phase 3 trial

Jul 22, 2022 10:59am